keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy induced cardiotoxicity

keyword
https://www.readbyqxmd.com/read/29783917/capecitabine-induced-myopericarditis-a-case-report-and-review-of-literature
#1
Sydney Saunders, Maria Anwar
Objective To describe a possible case of capecitabine-induced myopericarditis in a patient at the Cardio-Oncology Clinic in Calgary, AB. Design A literature search and adverse drug reaction assessment with the Naranjo tool was conducted. Results A 39-year-old male with recurrent locally advanced rectal adenocarcinoma presented two days after adjuvant treatment with capecitabine and oxaliplatin complaining of intermittent, severe interscapular pain. Based on symptoms, laboratory investigations, and imaging, the patient was diagnosed with acute myopericarditis...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29779119/a-chemosensitizer-drug-disulfiram-prevents-doxorubicin-induced-cardiac-dysfunction-and-oxidative-stress-in-rats
#2
Varsha K Sonawane, Umesh B Mahajan, Sachin D Shinde, Subhajit Chatterjee, Sandip S Chaudhari, Harshada A Bhangale, Shreesh Ojha, Sameer N Goyal, Chanakya N Kundu, Chandragouda R Patil
In the present study, the preventive effects of orally administered disulfiram (DS) against the doxorubicin (DOX)-induced cardiotoxicity were investigated in rats. DS was orally administered for 7 days at doses of 2, 10, and 50 mg/kg/day. DOX (30 mg/kg) was intraperitoneally administered on the 5th day of the initiation of DS treatment. Within 48 h of injection, DOX treatment significantly altered ECG, elevated the ST height, and increased the QT and QRS intervals. It reduced the cardiac levels of injury markers like creatine kinase isoenzyme-MB and lactate dehydrogenase...
May 10, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29764506/cardiotoxicity-of-5-fluorouracil-and-capecitabine-in-chinese-patients-a-prospective-study
#3
Jianjun Peng, Chao Dong, Chang Wang, Weihua Li, Hao Yu, Min Zhang, Qun Zhao, Bo Zhu, Jun Zhang, Wenliang Li, Fenghua Wang, Qiong Wu, Wenhao Zhou, Ying Yuan, Meng Qiu, Gong Chen
BACKGROUND: 5-Fluorouracil (5-FU) and capecitabine-associated cardiotoxicity ranging from asymptomatic electrocardiography (ECG) abnormalities to severe myocardial infarction has been reported in a number of studies, but such cardiotoxicity in Chinese patients with malignant diseases has not been investigated to date. In the present study, we aimed to prospectively evaluate the incidence rates and clinical manifestations of 5-FU- and capecitabine-associated cardiotoxicity in cancer patients recruited from multiple centers in China...
May 11, 2018: Cancer communications
https://www.readbyqxmd.com/read/29737469/serum-mir-30c-level-predicted-cardiotoxicity-in-non-small-cell-lung-cancer-patients-treated-with-bevacizumab
#4
Fang Zhou, Xike Lu, Xun Zhang
Cardiotoxicity is a common adverse effect induced by drug chemotherapy. miR-30c has been reported to be involved in the progress of heart diseases. In the present study, miR-30c was used to predict the cardiotoxicity in non-small cell lung cancer (NSCLC) patients treated with bevacizumab chemotherapy. Eighty NSCLC patients were included in this study. Serum miR-30c levels were detected at pre-chemotherapy, during-chemotherapy (the 2nd, 4th, and 8th week) and 1 month after chemotherapy. miR-30c expression was elevated with the duration of the chemotherapy cycle and decreased 1 month after chemotherapy...
May 8, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29737278/determining-the-genetic-basis-of-anthracycline-cardiotoxicity-by-response-qtl-mapping-in-induced-cardiomyocytes
#5
David A Knowles, Courtney K Burrows, John D Blischak, Kristen M Patterson, Daniel J Serie, Nadine Norton, Carole Ober, Jonathan K Pritchard, Yoav Gilad
Anthracycline-induced cardiotoxicity (ACT) is a key limiting factor in setting optimal chemotherapy regimes, with almost half of patients expected to develop congestive heart failure given high doses. However, the genetic basis of sensitivity to anthracyclines remains unclear. We created a panel of iPSC-derived cardiomyocytes from 45 individuals and performed RNA-seq after 24h exposure to varying doxorubicin dosages. The transcriptomic response is substantial: the majority of genes are differentially expressed and over 6000 genes show evidence of differential splicing, the later driven by reduced splicing fidelity in the presence of doxorubicin...
May 8, 2018: ELife
https://www.readbyqxmd.com/read/29713898/pharmacogenetics-of-chemotherapy-induced-cardiotoxicity
#6
REVIEW
Vivian Y Chang, Jessica J Wang
PURPOSE OF REVIEW: The goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. RECENT FINDINGS: Most of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended...
April 30, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29708912/chemotherapy-induced-cardiotoxicity-new-insights-into-mechanisms-monitoring-and-prevention
#7
Christian Cadeddu Dessalvi, Martino Deidda, Donato Mele, Pier P Bassareo, Roberta Esposito, Ciro Santoro, Maria Lembo, Maurizio Galderisi, Giuseppe Mercuro
: Chemotherapy-induced cardiotoxicity (CTX) remains a determining factor for the quality of life and mortality of patients treated with potentially cardiotoxic drugs. Considerable advances have been made in this field with increase in awareness regarding chemotherapy-induced CTX, which has changed the treatment approach to include cardiovascular risk among the first factors to be evaluated before therapy. Moreover, a better understanding of the pathophysiology of chemotherapy-induced CTX has also facilitated early identification of patients at risk with the help of new imaging technologies...
April 26, 2018: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/29698683/anticancer-drug-induced-cardiac-rhythm-disorders-current-knowledge-and-basic-underlying-mechanisms
#8
REVIEW
Joachim Alexandre, Javid Moslehi, Kevin R Bersell, Christian Funck-Brentano, Dan M Roden, Joe-Elie Salem
Significant advances in cancer treatment have resulted in decreased cancer related mortality for many malignancies with some cancer types now considered chronic diseases. Despite these improvements, there is increasing recognition that many cancer patients or cancer survivors can develop cardiovascular diseases, either due to the cancer itself or as a result of anticancer therapy. Much attention has focused on heart failure; however, other cardiotoxicities, notably cardiac rhythm disorders, can occur without underlying cardiomyopathy...
April 24, 2018: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29694546/subclinical-anthracycline-induced-cardiotoxicity-in-the-long-term-follow-up-of-lymphoma-survivors-a-multi-layer-speckle-tracking-analysis
#9
Yu Kang, Fei Xiao, Haiyan Chen, Wei Wang, Lijing Shen, Hang Zhao, Xuedong Shen, Fangyuan Chen, Ben He
BACKGROUND: Anthracycline generates progressive left ventricular dysfunction associated with a poor prognosis. OBJECTIVES: The purpose of this study was to evaluate whether layer-specific strain analysis could assess the subclinical left ventricular dysfunction after exposure to anthracycline. METHODS: Forty-two anthracycline-treated survivors of large B-cell non-Hodgkin lymphoma, aged 55.83 ± 17.92 years (chemotherapy group) and 27 healthy volunteers, aged 51...
March 2018: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/29687878/anthracycline-and-trastuzumab-induced-cardiotoxicity-in-breast-cancer
#10
M A Nicolazzi, A Carnicelli, M Fuorlo, A Scaldaferri, R Masetti, R Landolfi, A M R Favuzzi
OBJECTIVE: Breast cancer is the most common cancer among women. In the last twenty years early diagnosis, neoadjuvant and adjuvant systemic treatment that targeted to specific molecular targets have significantly reduced the mortality from breast cancer. However, the increase in survival has allowed to observe the cardiotoxic effects of anticancer therapy and increased mortality from cardiovascular causes, resulting in a large literature where experts try to identify the correct management of this critical problem...
April 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29644219/management-of-chemotherapy-induced-left-ventricular-dysfunction-and-heart-failure-in-patients-with-cancer-while-undergoing-cancer-treatment-the-md-anderson-practice
#11
Anecita P Fadol
Chemotherapy-induced cardiotoxicity resulting in heart failure (HF) is one of the most dreaded complications of cancer therapy that can significantly impact morbidity and mortality. With a high prevalence of cardiovascular disease in cancer patients, the risk of developing HF is significantly increased. A new discipline of Onco-Cardiology has evolved to address the cardiovascular needs of patients with cancer, however, there is limited evidence-based data to guide clinical decision-making in the management of the cardiovascular complications of cancer therapy...
2018: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29620051/manipulation-free-cultures-of-human-ipsc-derived-cardiomyocytes-offer-a-novel-screening-method-for-cardiotoxicity
#12
Sheeja Rajasingh, Dona Greta Isai, Saheli Samanta, Zhi-Gang Zhou, Buddhadeb Dawn, William H Kinsey, Andras Czirok, Johnson Rajasingh
Induced pluripotent stem cell (iPSC)-based cardiac regenerative medicine requires the efficient generation, structural soundness and proper functioning of mature cardiomyocytes, derived from the patient's somatic cells. The most important functional property of cardiomyocytes is the ability to contract. Currently available methods routinely used to test and quantify cardiomyocyte function involve techniques that are labor-intensive, invasive, require sophisticated instruments or can adversely affect cell vitality...
April 5, 2018: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29616409/cardiotoxicity-in-hematological-diseases-are-the-tyrosine-kinase-inhibitors-imatinib-and-nilotinib-safe
#13
Ana Rita G Francisco, Daniela Alves, Cláudio David, Lurdes Guerra, Fausto J Pinto, Ana G Almeida
Chemotherapy-induced cardiotoxicity is a growing concern. The cardiotoxic impact of new drugs such as tyrosine kinase inhibitors is unknown, especially the ones used for chronic myeloid leukemia. We aim to evaluate nilotinib- and imatinib-induced cardiotoxicity. Single-center prospective study of consecutive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors was conducted during 2015. Patients underwent an initial clinical, laboratorial and echocardiographic evaluation, repeated after 1 year...
April 3, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29615646/bile-acids-increase-doxorubicin-sensitivity-in-abcc1-expressing-tumour-cells
#14
Simon Chewchuk, Tyler Boorman, Derek Edwardson, Amadeo M Parissenti
Tumour cells possess or acquire various mechanisms to circumvent the cytotoxic effects of chemotherapy drugs. One such mechanism involves the overexpression of ABC transporters that facilitate the extrusion of a variety of structurally distinct chemotherapy drugs from the cytoplasm into the extracellular space. While specific ABC transporter inhibitors have been developed, many affect other ABC transporters, particularly at elevated concentrations. It is also unclear whether they show clear efficacy for combatting drug resistance in cancer patients with minimal host toxicity...
April 3, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29610292/renin-angiotensin-system-inhibitors-to-mitigate-cancer-treatment-related-adverse-events
#15
Matthias Pinter, Wilhelmus J Kwanten, Rakesh K Jain
Treatment-related side effects are a major clinical problem in cancer treatment. They lead to reduced compliance to therapy as well as increased morbidity and mortality. Well-known are the sequelae of chemotherapy on the heart, especially in childhood cancer survivors. Therefore, measures to mitigate the adverse events of cancer therapy may improve health and quality of life in cancer patients, both in short and long term. The renin angiotensin system (RAS) affects all hallmarks of cancer, and blockage of the RAS is associated with an improved outcome in several cancer types...
April 2, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29608498/cardioprotection-in-the-modern-era-of-cancer-chemotherapy
#16
Anuradha Godishala, Shu Yang, Aarti Asnani
The current arsenal of cancer chemotherapy is broad and rapidly expanding and includes conventional cytotoxic agents and targeted and immune-based therapies. As cancer survival rates have improved, the acute and latent cardiotoxicities of chemotherapy have emerged as important contributors to morbidity and mortality in cancer survivors. All chemotherapeutic agents have the potential for cardiac complications, with manifestations ranging from subclinical left ventricular dysfunction and asymptomatic QT prolongation, to congestive heart failure, myocardial ischemia, myocarditis, arrhythmia, and sudden cardiac death...
May 2018: Cardiology in Review
https://www.readbyqxmd.com/read/29603386/natural-history-of-myocardial-deformation-in-children-adolescents-and-young-adults-exposed-to-anthracyclines-systematic-review-and-meta-analysis
#17
Mirela Tuzovic, Pei-Tzu Wu, Samuel Kianmahd, Kim-Lien Nguyen
OBJECTIVE: Anthracyclines are widely used to treat solid and hematologic malignancies, but are known to cause cardiotoxicity. As more childhood cancer survivors reach adulthood due to improvements in oncologic treatments, they become susceptible to late and progressive anthracycline-induced cardiotoxicity. Nonetheless, diagnostic criteria for early detection of cardiac dysfunction are not well defined in children, adolescent, and young adults (CAYA, ages 1-40 years). We present a natural history of the changes in myocardial deformation in CAYA patients after anthracycline therapy...
March 30, 2018: Echocardiography
https://www.readbyqxmd.com/read/29593308/the-anti-cancer-multikinase-inhibitor-sorafenib-impairs-cardiac-contractility-by-reducing-phospholamban-phosphorylation-and-sarcoplasmic-calcium-transients
#18
Christopher Schneider, Markus Wallner, Ewald Kolesnik, Viktoria Herbst, Heinrich Mächler, Martin Pichler, Dirk von Lewinski, Simon Sedej, Peter P Rainer
Tyrosine-kinase inhibitors (TKIs) have revolutionized cancer therapy in recent years. Although more targeted than conventional chemotherapy, TKIs exhibit substantial cardiotoxicity, often manifesting as hypertension or heart failure. Here, we assessed myocyte intrinsic cardiotoxic effects of the TKI sorafenib and investigated underlying alterations of myocyte calcium homeostasis. We found that sorafenib reversibly decreased developed force in auxotonically contracting human myocardia (3 µM: -25 ± 4%, 10 µM: -29 ± 7%, 30 µM: -43 ± 12%, p < 0...
March 28, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29567630/anthracycline-induced-cardiotoxicity-a-multicenter-randomised-trial-comparing-two-strategies-for-guiding-prevention-with-enalapril-the-international-cardiooncology-society-one-trial
#19
Daniela Cardinale, Fabio Ciceri, Roberto Latini, Maria Grazia Franzosi, Maria Teresa Sandri, Maurizio Civelli, GianFranco Cucchi, Elisabetta Menatti, Maurizio Mangiavacchi, Raffaele Cavina, Enrico Barbieri, Stefania Gori, Alessandro Colombo, Giuseppe Curigliano, Michela Salvatici, Antonio Rizzo, Francesco Ghisoni, Alessandra Bianchi, Cristina Falci, Michele Aquilina, Andrea Rocca, Anna Monopoli, Carlo Milandri, Giuseppe Rossetti, Marco Bregni, Marco Sicuro, Alessandra Malossi, Daniele Nassiacos, Claudio Verusio, Monica Giordano, Lidia Staszewsky, Simona Barlera, Enrico B Nicolis, Michela Magnoli, Serge Masson, Carlo M Cipolla
BACKGROUND: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. METHODS: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals. Patients were randomly assigned to two strategies: enalapril in all patients started before chemotherapy (CT; 'prevention' arm), and enalapril started only in patients with an increase in troponin during or after CT ('troponin-triggered' arm)...
May 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29566148/co-administration-of-resveratrol-with-doxorubicin-in-young-mice-attenuates-detrimental-late-occurring-cardiovascular-changes
#20
Nobutoshi Matsumura, Beshay N Zordoky, Ian M Robertson, Shereen M Hamza, Nirmal Parajuli, Carrie-Lynn M Soltys, Donna L Beker, Marianne K Grant, Maria Razzoli, Alessandro Bartolomucci, Jason R B Dyck
AIMS: Doxorubicin (DOX) is among the most effective chemotherapies used in pediatric cancer patients. However, the clinical utility of DOX is offset by its well-known cardiotoxicity, which often does not appear until later in life. Since hypertension significantly increases the risk of late-onset heart failure in childhood cancer survivors, we investigated whether juvenile DOX exposure impairs the ability to adapt to angiotensin II (Ang II)-induced hypertension later in life as well as treatments that could prevent this...
March 16, 2018: Cardiovascular Research
keyword
keyword
112194
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"